share_log

Biodexa Pharmaceuticals | 424B3: Prospectus

Biodexa Pharmaceuticals | 424B3: Prospectus

Biodexa Pharmaceuticals | 424B3：募資說明書
美股sec公告 ·  05/03 16:13
Moomoo AI 已提取核心訊息
Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has filed a prospectus with the SEC under Rule 424(b)(3) for the resale of 492,000 ordinary shares represented by 1,230 American Depositary Shares (ADSs). These shares are related to warrants issued during private placements in October 2019 and May 2020, as well as placement agent warrants connected to these placements. The selling shareholders identified in the prospectus may sell the shares at market prices or negotiated transactions. Biodexa Pharmaceuticals will not receive proceeds from the sale of shares by the selling shareholders, except for potential proceeds from the exercise of the warrants. The company has also detailed the rights and obligations of ADS holders, including distribution of dividends, voting rights, and fees and charges. The prospectus includes legal considerations such as the enforcement of civil liabilities under UK law and the jurisdiction for legal proceedings. The company has appointed an agent for service of process in the U.S. and has outlined the expenses related to the offering.
Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has filed a prospectus with the SEC under Rule 424(b)(3) for the resale of 492,000 ordinary shares represented by 1,230 American Depositary Shares (ADSs). These shares are related to warrants issued during private placements in October 2019 and May 2020, as well as placement agent warrants connected to these placements. The selling shareholders identified in the prospectus may sell the shares at market prices or negotiated transactions. Biodexa Pharmaceuticals will not receive proceeds from the sale of shares by the selling shareholders, except for potential proceeds from the exercise of the warrants. The company has also detailed the rights and obligations of ADS holders, including distribution of dividends, voting rights, and fees and charges. The prospectus includes legal considerations such as the enforcement of civil liabilities under UK law and the jurisdiction for legal proceedings. The company has appointed an agent for service of process in the U.S. and has outlined the expenses related to the offering.
臨床階段的生物製藥公司Biodexa Pharmaceuticals PLC已根據第424（b）（3）條向美國證券交易委員會提交了招股說明書，要求轉售由1,230股美國存托股（ADS）代表的492,000股普通股。這些股票與2019年10月和2020年5月私募期間發行的認股權證以及與這些配售相關的配售代理認股權證有關。招股說明書中確定的出售股東可以按市場價格出售股票，也可以通過談判進行交易。除行使認股權證的潛在收益外，Biodexa Pharmicals不會獲得出售股東出售股票的收益。該公司還詳細說明了ADS持有人的權利和義務，包括股息分配、投票權以及費用和收費。招股說明書包括法律方面的考慮，例如根據英國法律執行民事責任和法律訴訟管轄權。該公司已在美國任命了一名代理人提供法律服務，並概述了與本次發行相關的費用。
臨床階段的生物製藥公司Biodexa Pharmaceuticals PLC已根據第424（b）（3）條向美國證券交易委員會提交了招股說明書，要求轉售由1,230股美國存托股（ADS）代表的492,000股普通股。這些股票與2019年10月和2020年5月私募期間發行的認股權證以及與這些配售相關的配售代理認股權證有關。招股說明書中確定的出售股東可以按市場價格出售股票，也可以通過談判進行交易。除行使認股權證的潛在收益外，Biodexa Pharmicals不會獲得出售股東出售股票的收益。該公司還詳細說明了ADS持有人的權利和義務，包括股息分配、投票權以及費用和收費。招股說明書包括法律方面的考慮，例如根據英國法律執行民事責任和法律訴訟管轄權。該公司已在美國任命了一名代理人提供法律服務，並概述了與本次發行相關的費用。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息